News

Stories

See all

The Power of Loxo Oncology at Lilly

View Story

Updates: Lilly's Global COVID-19 Response

View Story

From video approved by Jen Scroggins on Sept 14, 2020

The Impact of Osteoarthritis: Seeing the Person Behind the Pain

View Story

How Lilly Is Helping Discounts Reach People With Diabetes in 340B

View Story

Lilly Creates Mobile Research Units to Reach Elderly Patients

View Story

How Next Generation VBAs Can Put Patients Front and Center

View Story


Press Releases

See all

CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

September 18, 2020

Tags |  Product

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for




Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

September 17, 2020

Tags |  Corporate

Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments INDIANAPOLIS and THOUSAND OAKS, Calif. , Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to




Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

September 16, 2020

Tags |  Product

- Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points   - Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo--a 72 percent risk




Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care

September 15, 2020

Tags |  Corporate

INDIANAPOLIS , Sept. 15, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis.